Patents Assigned to Julius-Maximilians-Universitat
-
Patent number: 11927651Abstract: A system for one-sided measuring a presence of magnetic particles in a probe volume comprises a one-sided coil assembly and a current controller, wherein the one-sided coil assembly is arranged around a central coil assembly axis for generating a rotating magnetic field distribution and comprises at least 3, preferably at least 4, circumferentially distributed coil assembly sectors, wherein the current controller is configured to generate a time varying current in each of said coil assembly sectors, said time varying current comprising a periodic modulation with a rotation frequency and phase shifted between adjacent coil assembly sectors to generate a magnetic field rotating in a plane perpendicular to the coil assembly axis, said magnetic field rotating with a rotation frequency associated with a frequency of said periodic modulation, and wherein the system is configured for measuring said presence of magnetic particles in said probe volume with said one-sided coil assembly.Type: GrantFiled: February 21, 2020Date of Patent: March 12, 2024Assignee: Julius-Maximilians-Universität WürzburgInventors: Patrick Vogel, Martin Rückert
-
Patent number: 11891436Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.Type: GrantFiled: August 11, 2020Date of Patent: February 6, 2024Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Jörg Wischhusen, Markus Junker, Thomas Müller, Stefan Saremba
-
Patent number: 11866454Abstract: The present invention concerns a silane of formula (1) R1aSIR4-a??(1) where the group R1 or each of the groups R1 independently is bound to the silicon via an oxygen atom, comprises a straight or branched hydrocarbonaceous chain having one or more elements, wherein (a) each of the elements has not more than 8 consecutive carbon atoms, each of plural elements of the hydrocarbonaceous chain being separated from the next element by a cleavable group and/or (b) the elements have one or more cleavable groups and any hydrocarbonaceous chains remaining upon cleavage of said group(s) are water soluble, wherein said cleavable groups are selected from ester, anhydride, amide, carbonate, carbamate, ketal, acetal, disulfide, imine, hydrazone and oxime groups, has at least one thiol or a primary or secondary amino group, the group R or each of the groups R is independently a hydrolytically condensable group, and a is 1,2,3 or 4.Type: GrantFiled: May 29, 2019Date of Patent: January 9, 2024Assignees: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V., Julius-Maximilians-Universität WürzburgInventors: Herbert Wolter, Somchith Nique, Johannes Schwaiger
-
Patent number: 11760795Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine anti bodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.Type: GrantFiled: February 19, 2020Date of Patent: September 19, 2023Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Jörg Wischhusen, Markus Junker, Tina Schäfer, Dirk Pühringer
-
Patent number: 11738198Abstract: Methods of providing neuromodulation therapy to a patient are disclosed herein. In particular, methods of applying deep brain stimulation (DBS) for the treatment of Parkinson's disease (PD) and related disorders are disclosed. Aspects of the methods involve using stimulation waveforms having a first polarity (e.g., cathodic stimulation) to determine an optimum arrangement of electrodes for providing the therapy (i.e., identifying a sweet-spot for stimulation). Therapy is then provided using the optimum arrangement of electrodes to deliver stimulation waveforms having the opposite polarity (e.g., anodic stimulation).Type: GrantFiled: May 8, 2020Date of Patent: August 29, 2023Assignee: THE FREESTATE OF BAVARIA REPRESENTED BY THE JULIUS MAXIMILIANS-UNIVERSITÄT WÜRZBRGInventors: Jens Volkmann, Frank Steigerwald
-
Publication number: 20230028937Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: ApplicationFiled: June 22, 2022Publication date: January 26, 2023Applicant: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Publication number: 20220340681Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “A” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.Type: ApplicationFiled: June 17, 2022Publication date: October 27, 2022Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventor: Gernot Stuhler
-
Patent number: 11464856Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.Type: GrantFiled: September 30, 2016Date of Patent: October 11, 2022Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WürzburgInventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling, Tina Schäfer, Martina Selle
-
Patent number: 11457814Abstract: An apparatus for determining a disease parameter describing a type of cardiac disease includes a unit for reading input parameters representing 3D myocardial velocity fields with voxel wise 3D velocity information. The velocity vectors represent velocity of a voxel of a region of the heart at a predefined time point or time interval; a velocity vector depicts a voxel wise 3D velocity of the myocardium with different magnitude. A processor applies an algorithm to obtain a rotation parameter and/or strain-rate-tensor representing local curl of the input parameters and local rate of strain at a certain spatial point, at a certain time point or time interval. A processor calculates the disease parameter on the basis of the rotation parameter and strain-rate-tensor, dividing an absolute value of the rotation parameter by an eigenvalue. The disease parameter reflects a proportion to overall deformation of local layer shearing with regard to local pure deformation.Type: GrantFiled: May 29, 2019Date of Patent: October 4, 2022Assignees: FRAUNHOFER-GESELSCHAFT, JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Philipp Mörchel, Johannes Oberberger
-
Patent number: 11382526Abstract: A system for generating a traveling field free line, traveling along a propagation direction different from the orientation of said traveling field free line, said system comprising at least a first and a second coil assembly, wherein said first coil assembly is configured for generating a first stationary field free line at a first location when a current is flowing in the first coil assembly and the second coil assembly is current free, and wherein said second coil assembly is configured for generating a second stationary field free line at a second location, when a current is flowing in the second coil assembly and the first coil assembly is current free. The system further comprises a controller configured for driving the first and second coil assemblies with corresponding driving currents synchronized with each other, such that said traveling field free line travels along the propagation direction from a first location towards a second location.Type: GrantFiled: February 28, 2019Date of Patent: July 12, 2022Assignee: Julius-Maximilians-Universität WürzburgInventors: Patrick Vogel, Martin Rückert, Volker Christian Behr
-
Patent number: 11376578Abstract: The present invention relates to a device for the photocatalytic reduction of a substance with a structured reaction plate and/or a structured housing, wherein the reaction plate has, at least in some regions, a surface which contains a material with negative electron affinity and which can be electronically excited with radiation having a wavelength of ?180 nm.Type: GrantFiled: April 2, 2019Date of Patent: July 5, 2022Assignees: Fraunhofer-Gesellschaftzurförderung der angewandten Forschung e.V., Julius-Maximilians-Universität WürzburgInventors: Thomas Rehm, Anke Krüger
-
Publication number: 20220145332Abstract: The Sleeping Beauty (SB) transposon is an efficient non-viral tool for inserting transgenes into cells. Its broad utilization in gene therapy has been hampered by uncontrolled transposase gene activity and the inability to use transposase protein directly. The present invention concerns the finding that SB transposase spontaneously penetrates mammalian cells and can be delivered with transposon DNA to gene-modify various cell lines, embryonic, hematopoietic and induced pluripotent stem cells. The invention provides methods and compounds to apply the cell penetrating function of transposase in methods of genetically engineering cells as well as using the transposase as a shuttle for delivering cargo into a target cell or even into a target cell organelle. Genomic integration frequency can be titrated using the technology of the invention, which adds an additional layer of safety, opening opportunities for advanced applications in genetic engineering and gene therapy.Type: ApplicationFiled: February 19, 2020Publication date: May 12, 2022Applicants: European Molecular Biology Laboratory, Julius-Maximilians-Universität WürzburgInventors: Michael HUDECEK, Andreas MADES, Orsolya BARABAS, Cecilia Ines ZULIANI, Irma QUERQUES
-
Patent number: 11279963Abstract: The invention concerns a compound characterised by a mono(2-hydroxyethyl) terephthalic acid (MHET) and bis(2-hydroxyethyl) terephthalic acid chemically bonded to a saccharide. Furthermore, the invention concerns a corresponding compound which is used as a synthesis component for polymers or fine chemicals.Type: GrantFiled: March 23, 2017Date of Patent: March 22, 2022Assignee: Julius-Maximilians-Universität WürzburgInventors: Jürgen Seibel, Malte Timm
-
Patent number: 11262360Abstract: The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.Type: GrantFiled: September 30, 2016Date of Patent: March 1, 2022Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Jörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling
-
Patent number: 11154715Abstract: Methods for treating, reducing or reversing a motor deficit in a subject after a stroke comprising administering continuous electrical stimulation to the mesencephalic locomotor region (MLR) of the subject under sufficient conditions so as to treat, reduce or reverse the motor deficit of the subject are provided.Type: GrantFiled: April 24, 2019Date of Patent: October 26, 2021Assignee: Julius-Maximilians-Universität WürzburgInventors: Felix Fluri, Jens Volkmann
-
Patent number: 11149073Abstract: The invention relates to chimeric antigen receptors (CAR) with a humanized targeting domain specific to the antigen ROR1. The invention encompasses the polynucleotides, vectors encoding said CARs and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.Type: GrantFiled: April 27, 2018Date of Patent: October 19, 2021Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Michael Hudecek, Andreas Mades
-
Patent number: 11112472Abstract: A gradient system characterization function (e.g., a gradient system transfer function) may be developed by measuring a behavior of the MR device at a target temperature and developing at least one gradient system characterization function for a gradient coil of a magnetic resonance (MR) device at the target temperature based on the measured behavior. A patient may be subsequently imaged by the MR device, wherein the imaging process comprises measuring a temperature of a gradient coil, determining a gradient system characterization function at the measured temperature, calculating a pre-emphasized gradient of the gradient coil, and imaging the patient using the pre-emphasized magnetic field component.Type: GrantFiled: November 29, 2019Date of Patent: September 7, 2021Assignees: Siemens Healthcare GmbH, Julius-Maximilians-Universität Würzburg, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Gudrun Ruyters, Andrew Dewdney, Manuel Stich, Herbert Köstler, Christiane Pfaff, Tobias Wech, Adrienne Campbell
-
Publication number: 20210188997Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “?” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.Type: ApplicationFiled: March 1, 2019Publication date: June 24, 2021Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventor: Gernot STUHLER
-
Patent number: 11028144Abstract: A soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain for use in the treatment or prevention of a thrombotic disease in a subject, said treatment or prevention comprising administering to the subject an effective amount of said soluble polypeptide.Type: GrantFiled: December 23, 2016Date of Patent: June 8, 2021Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Bernhard Nieswandt, Sarah Beck, David Stegner
-
Publication number: 20210154651Abstract: The present invention relates to a device for the photocatalytic reduction of a substance with a structured reaction plate and/or a structured housing, wherein the reaction plate has, at least in some regions, a surface which contains a material with negative electron affinity and which can be electronically excited with radiation having a wavelength of ?180 nm.Type: ApplicationFiled: April 2, 2019Publication date: May 27, 2021Applicants: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V., JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Thomas REHM, Anke KRÜGER